Co-Diagnostics develops, manufactures and sells reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Co. may sell diagnostic equipment from other manufacturers as self-contained lab systems. Co. has a portable polymerase chain reaction (PCR) device that is designed to bring PCR to patients in point-of-care and even at-home settings. Co.'s diagnostics systems enable molecular testing for organisms and genetic diseases by automating procedures in both the development and administration of tests. The CODX average annual return since 2017 is shown above.
The Average Annual Return on the CODX average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CODX average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CODX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|